TP53 and acute myeloid leukemia: In the Assi et al. study, 24% of the de novo AML patients with normal diploid cytogenetic, regarded as an intermediate-risk category [334], had p53 overexpression, which was accompanied by lower platelet counts, lower frequency of CD34 expression in blasts, higher bone marrow blast counts, and a higher frequency of FLT3 internal tandem duplication in this subset of AML patients.